Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Income: 2015-2024

Historic Net Income for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.5 million.

  • Syndax Pharmaceuticals' Net Income fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
  • Syndax Pharmaceuticals' Net Income amounted to -$318.5 million in FY2024, which was down 52.40% from -$209.0 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Net Income ranged from a high of $24.7 million in FY2021 and a low of -$318.5 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$209.0 million (2023), whereas its average is -$225.5 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 133.90% in 2021, then crashed by 702.74% in 2022.
  • Syndax Pharmaceuticals' Net Income (Yearly) stood at -$72.9 million in 2020, then soared by 133.90% to $24.7 million in 2021, then slumped by 702.74% to -$149.0 million in 2022, then crashed by 40.25% to -$209.0 million in 2023, then crashed by 52.40% to -$318.5 million in 2024.